•
Mar 31, 2019

Viking Therapeutics Q1 2019 Earnings Report

EPS
-$0.07
Previous year: -$0.1
-30.0%
R&D Expenses
$4.5M
G&A Expenses
$2.31M
Cash and Equivalents
$14.3M
Previous year: $36.4M
-60.5%
Total Assets
$300M
Previous year: $79M
+280.0%

Viking Therapeutics

Viking Therapeutics